ERBB2 and breast cancer: Similarly, in the BOLERO-2 phase III trial, randomizing HR+/HER2- metastatic BC patients to receive Everolimus plus Exemestane versus placebo plus Exemestane, PTEN mutations or low PTEN protein expression assessed on tumor samples were not associated with Everolimus benefit [36].